Patrick Cox

The big story of the next year will be what I call the “phytochemical and nutraceutical revolution.”

Phytochemicals, as you may know, are chemical compounds that occur naturally in plants. Nutraceuticals are plant- or animal-derived products. Both, however, are meant to provide health benefits.

While these compounds may function exactly like FDA-approved pharmaceuticals, they are not categorized as such.

As investors, this gives you and me a huge opportunity to invest in early-stage, revolutionary companies working on plant- and animal-based health solutions that bypass the lengthy and extremely expensive FDA approval process.

Now, as you know, there’s nothing new about phytochemical usage…

The Greeks used many plant products, including salicin, from which modern aspirin comes. Ayurvedic medicine from ancient India relied on a wide variety of medically useful phytochemicals, including the anti-diabetes compound pterostilbene, derived from pterocarpus marsupium, or the Indian kino tree.

There’s a common assumption among proponents of “natural products” that phytochemicals are inherently safe because they are part of “nature.” Many phytochemicals, however, are extremely toxic. Cyanide and hemlock, the poison that killed Socrates, are natural products that can easily kill you.

This naiveté, often bolstered with the pseudoscience and outright fraud common in health food store culture, in the past made me extremely cynical about the promise of phytochemicals, except for basic essential nutrients.

I was, however, wrong.

Clearly, I underestimated the impact of Moore’s law, the accelerating power of computer technologies, on biotechnology. The tools needed to find effective phytochemicals, as well as the biological mechanisms behind their actions, have plummeted in price.

At the same time, the burden of regulation has increased.

Recently, I’ve heard from biotech executives that the Obama administration is afraid of medical innovation because of the mistaken belief that new therapies will increase the cost of health care, which they have a political interest in keeping down.

These two forces have combined to change the economics of drug discovery, shifting the focus toward natural, as opposed to man-made, compounds.

In short, the “phytochemical and nutraceutical revolution” has begun.

My first exposure to this phenomenon was through a company I’ve recommended to my Breakthrough Technology Alert readers called Galectin Therapeutics (NASDAQ:GALT). The company’s cancer- and fibrosis-fighting compounds are, in fact, naturally occurring plant sugars. Currently, they have to be administered via transfusion, but that will, inevitably, change.

Galectin Therapeutics’ galectin-3 blocking natural plant sugars are one of the most-important biotech breakthroughs of our era. Not only do their phytochemicals pierce the cancer-cloaking shield, they also reverse fibrosis.

The prestigious Ludwig Institute is in clinical tests right now with Galectin Therapeutics’ drug candidate in conjunction with a cancer vaccine. Just yesterday, however, the company announced plans to initiate clinical trials for NASH, or fatty liver disease, in early 2013.

Let me repeat that for those who weren’t paying close attention: early 2013.

Another company I’ve recommended has created a synthesized form of a natural alkaloid that I believe will extend healthy life spans. Equity in the company that makes this product could yield truly transformational returns.

I believe this company has a product that actually does what other supplements only wished they could do — it controls chronic low-level inflammation.

That effect may not sound very important. But as I explained in a recent issue of The Penny Sleuth, it is actually revolutionary.

The name of the neural circuit that regulates the immune response to injury and invasion is the “inflammatory reflex.” Inflammation is an extremely complex mechanism that involves the destruction through apoptosis of damaged cells, the healing of salvageable cells and the growth of entirely new cells. The primary role of this important biological response is to heal injury or infection.

In fact, in the “olden days” before penicillin, being thrown from a horse, kicked by a cow or bitten by any kind of animal was a potentially life-ending matter. The only way to survive a nearly inevitable sequence of injuries throughout a lifetime was to possess a strong inflammatory immune response. If individuals didn’t have the ability to mount a powerful inflammatory response, they were unlikely to live long enough to pass on their DNA.

But there is also a downside to the “inflammatory reflex.”

In the last decade or so, it has become increasingly clear that inflammation plays a major complicating role in almost all diseases. In fact, inflammation increases the rate of aging itself and leads to various pathologies. This is why your dentist lectures you about flossing. Inflammation from unhealthy gums increases the odds of getting heart disease and even Alzheimer’s.

Even with perfect gums, however, chronic inflammation increases as you age. Eventually, it cascades into a serious problem.

Uncontrolled inflammation causes the simultaneous healing and destruction of cells. This can lead to cancers, heart attacks, lupus, IBS, macular degeneration, stroke, obesity, ED, allergies, psoriasis, Crohn’s disease, endometriosis, rheumatoid arthritis, hair loss, diseases of the organs such as the thyroid and liver as well as…well, you name it.

Clearly, the potential market for such a “miracle drug” is enormous… and that’s why I am excited about the company that makes this product. But we are still in the early days of this story, which is probably why the company’s stock has not yet “run away.”

In conclusion, the “phytochemical and nutraceutical revolution” has begun.

To position yourself properly, I suggest looking at companies with the science and technology to produce these compounds…which bypass the increasingly regulated health care system.

Regards,

Patrick Cox
for The Daily Reckoning

Patrick Cox

Patrick Cox has lived deep inside the world of transformative technologies for over 25 years. This expertise lead him to Mauldin Economics, where he now heads Transformational Technology Alert.

  • R Davis

    Up North in Australia, there is a Natural Compound, which when injected into a cancerous tumor – shrinks that cancerous tumor – to nothing – within weeks.

    This Natural compound was discovered & has been developed by a husband & wife scientist team – and has been trialed on beloved pets who were soon to be dead of cancer – with a 100% success rate.
    This story was true & was presented on TV – then it all just disappeared.
    We will never see this product on our “things to try ” on our cancer cure list.
    Because cancer is a major killer & money spinner.
    Great investment advice.
    But with so many scams & snake oil salesmen about .

    Thanks but no thanks.

  • Yo Pumpin

    Same article was published May 29, 2012.

    Buddy John Maudlin is a director.

    Kinda fishy.

  • tdm

    or…the government will make new laws to regulate it.

Recent Articles

Addison Wiggin
The Central Bank Experiment that’s Destroying the Economy

Addison Wiggin

When it comes to central bankers and the global economy, you might say the inmates are running the asylum. Today, Addison Wiggin sits down with Jim Rickards to discuss the ever-changing world of finance, the likelihood of hyperinflation hitting the U.S., and the massive economic experiment being conducted by the world's central bankers. Read on...


Laissez Faire
The Real Reason ISIS Wants You Dead

Chris Campbell

ISIS is a radical terrorist organization wreaking havoc across Northern Iraq. But its members come from all over the world - including many from Western Countries. The question no one's asking is why... Why are foreigners flocking to the Middle East to fight alongside ISIS? And how far does Obama really want to go? Chris Campbell explores...


How to Trade October Volatility

Greg Guenthner

When it comes to the stock market, October gets a bad rap. It's true, there have been some major crashes in October (ahem... Black Monday, Black Tuesday, etc.) but on a shorter timeline this month hasn't been nearly as bad as you might think. Today, Greg Guenthner offers an optimistic look at the month investors love to hate. Read on...


What the Reboot of the US Budget Means for Your Money

Byron King

Big government doesn't come cheap. And right now the U.S. government is one of the biggest in history. So far the budget writers have been able to move money around to keep the machine moving. But as Byron King points out, that will soon become much more difficult. Read on for the full story...


Invest Like a Shark in the “New” Stock Market

Wayne Mulligan

In the late '90s, financial TV personalities like Jim Cramer became mega stars - often drawing more ratings the ESPN. But that was over 15 years ago... That couldn't happen again, could it? Today, Wayne Mulligan details the new flock of personalities that are set to cash-in on a different kind of investment boom. Read on...